ASX Announcement

08 Dec 2021

emyria
myriad data.
individual care.

Positive initial MDMA-analogue screening results and lodgement of patent

Highlights:

- In vitro receptor screening results for the first batch of MDMA analogues have been received from Eurofins (EPA:ERF)
- Results have highlighted a number of novel compounds with greater potency compared with MDMA for certain neuroreceptors at the test concentrations
- 66 of the 68 sent compounds screened demonstrated no interactions with the selected anti-targets (receptors and enzymes known to be involved in unwanted side effects)
- Second batch of compounds from the original analogue library of > 100 compounds now being prepared for initial screening
- First patent family successfully filed, further IP generation underway
- New MDMA analogues are now being created to expand the analogue library
- Collaboration between Emyria and Professor Iain McGregor (University of Sydney) to select follow-on screening assessments to help identify compounds with the greatest potential to help patients in need of registered therapeutics

Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development and care delivery company, is pleased to announce positive results have been received for the first batch of MDMA-analogues screened for neuroreceptor activity with major pharmaceutical development company, Eurofins. (*See ASX announcement 19 Oct 2021*).

The first patent family has been filed supported by the initial screening data.

66 of 68 compounds from the initial batch successfully passed screening with no evidence of interactions with one or more of the "anti-targets" - that is, enzyme or cell receptor interactions associated with unwanted side effects - at the test concentrations.

The remaining compounds are now being evaluated for further screening and dose-response analysis with Eurofins guided by Emyria's key advisors, A/Prof Matt Piggott and Prof Mat Martin-Iverson *(See ASX announcements 05 and 20 August 2021)*

Emyria collaborating with Professor Iain McGregor of the University of Sydney to select and prioritise the lead compounds as well as select suitable models that can help predict the therapeutic potential of the hit compounds identified from in vitro screening.

Professor Iain McGregor has expertise in human and preclinical psychopharmacology and the development of small molecules to modulate social and addictive behaviours. Iain is currently Professor of Psychopharmacology and Academic Director of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney. Professor McGregor's research interests also involve characterising the effects of novel psychoactive substances such as synthetic cannabinoids, synthetic cathinones and novel hallucinogens.

A second selection of compounds is currently being prepared for initial screening with Eurofins.

Additional novel compound synthesis has also commenced in collaboration with UWA to expand the analogue library.

Emyria's Managing Director, Dr. Michael Winlo said: *"These early results are promising with very few compounds excluded due to possible off-target concerns at the test concentrations. These results mean we have multiple compounds with therapeutic potential suitable for further screening and development.*

The MDMA analogue development program is progressing well. Our first patent has been filed and further IP filing is in progress. We are currently preparing the second selection of compounds for screening and have already started to synthesise new compounds which will further expand our drug discovery pipeline.

We are also very pleased to be working with Professor Iain McGregor, an expert in characterising the effects of novel psychoactive substances to complement the skills of A/Prof Matt Piggott, Prof Mat Martin-Iverson, and assisted by Eurofins, to lead the follow-on screening and evaluation of this library.

I look forward to updating the market with further progress and results as we advance against our development milestones in the coming months."

This announcement has been approved and authorised for release by the Board of Emyria Limited

For further information:

Dr. Michael Winlo
Managing Director
1300 436 363
mwinlo@emyria.com

Lexi O'Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au

Andrew Williams
Media Relations
+61 (0) 412 614 125
andreww@profilemedia.com.au

.

The MDMA analogy library

Emyria recently secured exclusive rights to a library of more than 100 novel MDMA analogues from the University of Western Australia creating a unique drug-discovery pipeline. *(See ASX announcement 05 Aug 2021)*

The library of compounds has been compiled by the highly regarded research group led by medicinal chemist, A. Prof. Matt Piggott, who has been working with MDMA analogues, and exploring their therapeutic potential, for more than 10 years

Emyria aims to screen and expand the existing library in order to identify families of patentable compounds with the greatest promise as new psychedelic-assisted therapies and treatments for other neurological disorders

The program has the potential to result in the commercialisation of multiple, novel, CNS-active compounds to help treat patients with major unmet needs.

About Emyria (www.emyria.com)

Emyria Limited is a data-backed clinical drug development and care delivery company focused on accelerating treatment development and improving patient care.

Emyria's Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria's drug development programs are informed by insights generated from extensive analysis of **Emyria Data** - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria's independent clinical services (**Emerald Clinics** - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.